James L Abbruzzese
Overview
Explore the profile of James L Abbruzzese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
312
Citations
16339
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang Z, Li Z, Wang X, Kang Y, Yuan Y, Niu J, et al.
Clin Cancer Res
. 2024 Dec;
30(23):5495.
PMID: 39618198
No abstract available.
2.
Liu Y, Li J, Lyu J, Howard L, Sibley A, Starr M, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Oct;
34(1):93-99.
PMID: 39400560
Background: Biomarker analyses are an integral part of cancer research. Despite the intense efforts to identify and characterize biomarkers in patients with cancer, little is known regarding the natural variation...
3.
Liu J, Xiong N, Wenham R, Wahner-Hendrickson A, Armstrong D, Chan N, et al.
Gynecol Oncol
. 2024 May;
187:105-112.
PMID: 38759516
Objective: Combination cediranib/olaparib has reported activity in relapsed ovarian cancer. This phase 2 trial investigated the activity of cediranib/olaparib in relapsed ovarian cancer and its association with homologous recombination deficiency...
4.
Gonzalez-Ochoa E, Milosevic M, Corr B, Abbruzzese J, Girda E, Miller R, et al.
Int J Gynecol Cancer
. 2023 Jun;
33(8):1208-1214.
PMID: 37380217
Objective: Wee1 kinase is a crucial regulator of the G2/M checkpoint which prevents entry of damaged DNA into mitosis. Adavosertib (AZD1775), a selective inhibitor of Wee1, induces G2 escape and...
5.
Zhu L, Ji J, Ma J, Wang D, Liu M, Du J, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681705
KRAS mutations are prevalent in patients with pancreatic ductal adenocarcinoma (PDAC) and are critical to fostering tumor growth in part by aberrantly rewiring glucose, amino acid, and lipid metabolism. Obesity...
6.
Schoenfeld J, Giobbie-Hurder A, Ranasinghe S, Kao K, Lako A, Tsuji J, et al.
Lancet Oncol
. 2022 Jan;
23(2):279-291.
PMID: 35033226
Background: Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy could enhance antitumour immunity. Therefore, we investigated...
7.
Green M, Bell J, Hubbard C, McCall S, McKinney M, Riedel J, et al.
JCO Precis Oncol
. 2021 Sep;
5.
PMID: 34568718
Patients And Methods: MRT is an internally developed system that aggregates and normalizes genomic profiling results from multiple sources. MRT serves as the foundation for our MTB, a team that...
8.
Luo Y, Li X, Ma J, Abbruzzese J, Lu W
Cancers (Basel)
. 2021 Mar;
13(4).
PMID: 33668583
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies and (Kirsten rat sarcoma 2 viral oncogene homolog) mutations have been considered a critical driver of PDAC initiation and...
9.
Moschos S, Eroglu Z, Khushalani N, Kendra K, Ansstas G, In G, et al.
Melanoma Res
. 2021 Mar;
31(2):162-172.
PMID: 33661190
Background: IL-2 inducible kinase (ITK) is highly expressed in metastatic melanomas and its inhibition suppresses melanoma cell proliferation. We hypothesize that ibrutinib has a direct antitumor effect in melanoma cell...
10.
Liu M, Wang D, Luo Y, Hu L, Bi Y, Ji J, et al.
Cell Death Dis
. 2021 Feb;
12(2):189.
PMID: 33594044
Oncogenic RAS is a critical driver for the initiation and progression of several types of cancers. However, effective therapeutic strategies by targeting RAS, in particular RAS and RAS, and associated...